GSK chief executive officer Emma Walmsley in London.
Photographer: Jaimi Joy/Bloomberg
GSK CEO Says She's Already Tariff-Proofing Britain's Global Drugmaker
Emma Walmsley on navigating global politics and why inclusion still matters
In her eight-year tenure as chief executive officer of GSK Plc, Emma Walmsley has seen off a combative activist investor, navigated multi-billion dollar litigation in the US and spun out a consumer health company, Haleon Plc. Her latest challenge is preparing the drugmaker for the looming threat of getting dragged into President Donald Trump’s trade war.
The 55-year-old has worked to turn GSK — which traces its history to the 18th century — into a forward-looking pharma company by embracing new developments, including pivoting back to cancer medicines and investing in artificial intelligence. Still, with the share price stubbornly low, she’s facing pressure from investors to improve performance.